Pfizer Stock News

13F filings this week will reveal hedge fund and institutional moves, offering insight into smart money positioning amid recent market highs. Earnings season is winding down, with 90% of S&P 500 companies reporting; most beat estimates, but guidance remains cautious.

Der US-Pharmariese Pfizer US7170811035 ist als Gewinner aus dem Bieterwettkampf mit dem Rivalen Novo Nordisk DK0062498333 um die US-Adipositas-Spezialistin Metsera US59267L1070 hervorgegangen.

Metsera accepted a sweetened offer from Pfizer late on Friday, citing U.S. antitrust risks in Novo's bid that it had previously called superior.

Pfizer acquires Metsera for $10 billion, cementing their new obesity treatment strategy. The purchase concludes a weeklong bidding frenzy between the New York-based pharmaceutical company and Danish heavyweight Novo Nordisk, whose last-minute counterbid was finally rejected by US antitrust regulators.

Coca-Cola owes its remarkable dividend streak to its brand name, pricing power, and new products. Pfizer is struggling right now, but its future looks bright considering recent moves and a cheap valuation.

AbbVie's and Pfizer's Q3 earnings and dividend updates prompt a rating upgrade to Hold for ABBV and reiteration of Sell for PFE. PFE's higher yield (almost 7%) and single-digit P/E (FY1 P/E is ~8x only) can be attractive for deep value investors. The high yield and cheap valuation are for good reasons.

Pfizer prevails over rival Novo Nordisk after an unusual bidding war for the weight-loss startup.

Pfizer has submitted a sweetened bid for obesity drug developer Metsera , as its fight against rival Novo Nordisk escalates, Bloomberg News reported on Friday.